APP and Alzheimer disease: The decrease in the number of pyramidal cells and thickness of CA1 and CA3 regions have also been reported in Alzheimer’s-like disease induced by scopolamine [45] and in APP/PS1 transgenic mouse models of Alzheimer's disease [46].